These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 29187601)
1. Efficient solid-phase synthesis of meningococcal capsular oligosaccharides enables simple and fast chemoenzymatic vaccine production. Fiebig T; Litschko C; Freiberger F; Bethe A; Berger M; Gerardy-Schahn R J Biol Chem; 2018 Jan; 293(3):953-962. PubMed ID: 29187601 [No Abstract] [Full Text] [Related]
2. Functional expression of the capsule polymerase of Neisseria meningitidis serogroup X: a new perspective for vaccine development. Fiebig T; Berti F; Freiberger F; Pinto V; Claus H; Romano MR; Proietti D; Brogioni B; Stummeyer K; Berger M; Vogel U; Costantino P; Gerardy-Schahn R Glycobiology; 2014 Feb; 24(2):150-8. PubMed ID: 24259400 [TBL] [Abstract][Full Text] [Related]
3. Combined Chemical Synthesis and Tailored Enzymatic Elongation Provide Fully Synthetic and Conjugation-Ready Neisseria meningitidis Serogroup X Vaccine Antigens. Oldrini D; Fiebig T; Romano MR; Proietti D; Berger M; Tontini M; De Ricco R; Santini L; Morelli L; Lay L; Gerardy-Schahn R; Berti F; Adamo R ACS Chem Biol; 2018 Apr; 13(4):984-994. PubMed ID: 29481045 [TBL] [Abstract][Full Text] [Related]
4. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Micoli F; Romano MR; Tontini M; Cappelletti E; Gavini M; Proietti D; Rondini S; Swennen E; Santini L; Filippini S; Balocchi C; Adamo R; Pluschke G; Norheim G; Pollard A; Saul A; Rappuoli R; MacLennan CA; Berti F; Costantino P Proc Natl Acad Sci U S A; 2013 Nov; 110(47):19077-82. PubMed ID: 24191022 [TBL] [Abstract][Full Text] [Related]
5. Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs. Berti F; Micoli F Curr Opin Immunol; 2020 Aug; 65():42-49. PubMed ID: 32361591 [TBL] [Abstract][Full Text] [Related]
6. Structure of a protective epitope reveals the importance of acetylation of Henriques P; Dello Iacono L; Gimeno A; Biolchi A; Romano MR; Arda A; Bernardes GJL; Jimenez-Barbero J; Berti F; Rappuoli R; Adamo R Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29795-29802. PubMed ID: 33158970 [TBL] [Abstract][Full Text] [Related]
8. Characterization of the meningococcal serogroup X capsule N-acetylglucosamine-1-phosphotransferase. Muindi KM; McCarthy PC; Wang T; Vionnet J; Battistel M; Jankowska E; Vann WF Glycobiology; 2014 Feb; 24(2):139-49. PubMed ID: 24134880 [TBL] [Abstract][Full Text] [Related]
9. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development. Jennings HJ Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499 [No Abstract] [Full Text] [Related]
10. Chemoenzymatic synthesis of immunogenic meningococcal group C polysialic acid-tetanus Hc fragment glycoconjugates. McCarthy PC; Saksena R; Peterson DC; Lee CH; An Y; Cipollo JF; Vann WF Glycoconj J; 2013 Dec; 30(9):857-70. PubMed ID: 23949787 [TBL] [Abstract][Full Text] [Related]
11. Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W135. Bardotti A; Averani G; Berti F; Berti S; Galli C; Giannini S; Fabbri B; Proietti D; Ravenscroft N; Ricci S Vaccine; 2005 Mar; 23(16):1887-99. PubMed ID: 15734061 [TBL] [Abstract][Full Text] [Related]
12. PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine. Huang Q; Li D; Kang A; An W; Fan B; Ma X; Ma G; Su Z; Hu T J Control Release; 2013 Nov; 172(1):382-389. PubMed ID: 23511718 [TBL] [Abstract][Full Text] [Related]
13. Development of new vaccines against meningococcal disease. Bröker M Arzneimittelforschung; 2003; 53(12):805-13. PubMed ID: 14732960 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of impact of temperature and pH alterations on the size and antigenicity of meningococcal serogroup A and X polysaccharides and conjugates. Sharma N; Hanif S; Rana R; Upadhyay D; Chhikara MK Vaccine; 2019 Feb; 37(7):965-972. PubMed ID: 30651197 [TBL] [Abstract][Full Text] [Related]
15. Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines. Sun X; Stefanetti G; Berti F; Kasper DL Proc Natl Acad Sci U S A; 2019 Jan; 116(1):193-198. PubMed ID: 30510007 [TBL] [Abstract][Full Text] [Related]